Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) saw a large decrease in short interest in July. As of July 15th, there was short interest totalling 2,030,000 shares, a decrease of 27.2% from the June 30th total of 2,790,000 shares. Approximately 5.9% of the company’s shares are short sold. Based on an average daily volume of 941,600 shares, the short-interest ratio is currently 2.2 days.
Athira Pharma Trading Down 4.0 %
Shares of Athira Pharma stock opened at $3.34 on Tuesday. Athira Pharma has a 1 year low of $2.53 and a 1 year high of $16.65. The company has a 50-day moving average of $5.57 and a 200 day moving average of $8.70.
Athira Pharma (NASDAQ:ATHA – Get Rating) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.07. Equities research analysts forecast that Athira Pharma will post -2.67 EPS for the current fiscal year.
Institutional Trading of Athira Pharma
Several institutional investors have recently bought and sold shares of the company. Wasatch Advisors Inc. boosted its holdings in shares of Athira Pharma by 38.6% during the 4th quarter. Wasatch Advisors Inc. now owns 1,242,423 shares of the company’s stock valued at $16,189,000 after acquiring an additional 346,140 shares during the last quarter. State Street Corp boosted its holdings in shares of Athira Pharma by 39.0% during the 1st quarter. State Street Corp now owns 827,574 shares of the company’s stock valued at $11,172,000 after acquiring an additional 232,280 shares during the last quarter. Woodline Partners LP purchased a new stake in shares of Athira Pharma during the 1st quarter valued at about $2,667,000. Bank of America Corp DE boosted its holdings in shares of Athira Pharma by 50.8% during the 1st quarter. Bank of America Corp DE now owns 358,742 shares of the company’s stock valued at $4,843,000 after acquiring an additional 120,876 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in shares of Athira Pharma during the 1st quarter valued at about $1,427,000. 69.76% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have commented on ATHA. Jefferies Financial Group lowered shares of Athira Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, June 22nd. Stifel Nicolaus lowered shares of Athira Pharma from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $36.00 to $5.00 in a report on Thursday, June 23rd. Mizuho began coverage on shares of Athira Pharma in a report on Wednesday, July 6th. They issued a “buy” rating and a $6.00 price objective for the company. Berenberg Bank began coverage on shares of Athira Pharma in a report on Thursday, April 21st. They issued a “buy” rating and a $33.00 price objective for the company. Finally, BTIG Research began coverage on shares of Athira Pharma in a report on Tuesday, May 10th. They issued a “buy” rating and a $33.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Athira Pharma currently has an average rating of “Hold” and an average price target of $24.00.
About Athira Pharma
Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease.
- Get a free copy of the StockNews.com research report on Athira Pharma (ATHA)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- Deep Value High Yield Newell Brands Is Ready To Bottom
- The Colgate-Palmolive Growth Outlook Brightens
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.